Heart failure & cardiomyopathies
Transcriptomics Identifies a Small Set of Circulating Biomarkers and Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy
Authors' conclusion
Comprehensive plasma transcriptomics profiling identified a small set of circulating miRNAs to distinguish HCM from other cardiomyopathies with LVH.
Study context
- Population
- Cases with hypertrophic cardiomyopathy (HCM) and controls with hypertensive left ventricular hypertrophy (LVH), transthyretin amyloid cardiomyopathy (ATTR-CM), and aortic stenosis (AS)patients by disease group · HCM 294 · hypertensive LVH 321 · ATTR-CM 167 · AS 38
- Index test or model
- Logistic regression model using the 3 selected plasma microRNA (miRNAs) to distinguish HCM from other cardiomyopathies with LVH (hypertensive LVH, ATTR-CM, AS)
- Target condition
- hypertrophic cardiomyopathy (HCM)
Methodological detailscomprehensive plasma transcriptomics profiling, chronological split into training and test sets
- Comprehensive plasma transcriptomics profiling
- Chronological split into training and test sets
Performance
As reported in the abstract
Area under the receiver-operating characteristic curve
0.95
95% CI 0.93–0.97
Sensitivity
0.95
Specificity
0.90
Further findings
- miRNAs analyzed
- 2,656
- miRNAs identified (miR-454-3p, miR-98-5p, and miR-5581-3p)
- 3
Original publication
Transcriptomics Identifies a Small Set of Circulating Biomarkers and Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy. JACC Heart Fail. Published 24 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →